1-6 ± 0-3 3 0 ± 0 4 3-3 ± 0-5 4-7 ± 0-6 1-7 i 0 4 2-9 ± 0-4 Arm fibrinolytic capacity 14-2 ± 2-6 12-5 ± 1-9 14-3 ± 2-2 17 5 ± 2-3 16-8 ± 2-9 13-9 ± 2-5 Leg fibrinolytic capacity 3-2 ± 0-6 8-0 ± 1-0 9 1 ± 1-5 8-6 ± 2-0 3-1 ± 0 7 5-6 ± 0-7 occlusion is due to the release of plasminogen activator from the vein wall13 our findings may be explained in two ways: there may be a decrease in the leg vein wall activator early after tissue injury, or the release of activator from the wall may be impaired. Whatever the mechanism, however, the difference between the changes in the fibrinolytic capacities of the arm and leg may be one explanation for the relative frequency of venous thrombosis in the legs compared with the arms after fracture of the femoral shaft and myocardial infarction. The early depression of leg fibrinolytic capacity may also be relevant to the observation that deep venous thrombosis usually starts at the time of or very soon after tissue injury.1 3 4 Our findings conflict with those of Karaca and Nilsson,14 who reported that the fibrinolytic capacity of the legs, in contrast to that of the arms, was increased after prolonged recumbency. One explanation for the differing conclusions is that these investigators studied different groups of individuals whereas we examined the same people sequentially.
The origin of the plasminogen activator responsible for the fibrinolytic activity of systemic blood is unknown. The close correlation between the fibrinolytic capacity of the legs and the systemic fibrinolytic activity suggests, however, that the leg veins are one important source of circulating plasminogen activator.
Patients and Methods
Patients between 28 and 40 weeks of gestation were selected at random from inpatients used to counting fetal movements. The investigation was conducted in three parts-(1) assessment of fetal response to external cardiotocography using Doppler ultrasound with two different instruments to see whether it was due to an instrumental peculiarity; (2) a "sham" study to confirm objectivity; and (3) evaluation of the possibility that electrical currents from the apparatus stimulated fetal activity. This was achieved by occluding the transmission of ultrasound while retaining electrical contact.
In the first part of the study the Sonicaid FM2 and HewlettPackard 8025B cardiotocographs were used. Each has two abdominal inputs. One, the "tocograph head," detects the fetal heart beat using continuous Doppler ultrasound. The Sonicaid FM2 "ultrasonic head" consists of one transmitter and six peripheral ceramic receiving crystals; the HIewlett-Packard incorporates one transmitter and one receiving crystal. The ultrasonic energy output of the Sonicaid machine is about 12 mW/cm2 of transducer head, and that of the Hewlett-Packard about 16 mW/cm2 (manufacturers' data). In the second and third parts of the study only the Sonicaid FM2 was used.
Part 1-Fifteen patients were studied, eight with the Sonicaid FM2 and seven with the Hewlett-Packard 8025B. All rested before the investigation and were lying supine. The tocograph head was placed on the abdomen in the midline over the uterine fundus. The ultrasonic head was smeared with Aquasonic 100 gel and placed where the fetal heart was most clearly heard. Both heads of the monitor were held in position by Tubigrip bandage. Each patient was studied for 30 minutes. During the first 15 minutes uterine activity alone was recorded, and then, unknown to the patient, the ultrasonic head was activated. The patient counted the number of fetal movements during both periods. A high degree of correlation exists between electromagnetic recording and the maternal assessment of fetal movements,1 which was therefore used as the index of fetal activity.
Part 2-Sham studies were performed on a further six patients under conditions identical with those in part 1 but without activating the ultrasonic head.
Part 3-A further 15 patients were studied for three successive 15-minute periods. A circular brass collar was fitted to the ultrasonic head, so that though the collar was in contact with the abdomen an "air cell" existed between the skin and the transmitter and receiver. This was packed with polyvinyl foam (see fig.) . The brass collar allowed electric currents if any to be conducted between the ultrasonic head and the skin, and the air cell impaired the transmission of ultrasound. During the first period the ultrasonic head with the intervening air cell was placed on the abdomen but the head was not activated. In the second period the ultrasonic head with the intervening air cell was activated. Finally, the activated ultrasonic head without the air cell was used. The fetal movement count was recorded for each period.
In all cases the recording face of the monitor was out of sight of the patient. The procedure was evaluated by a clinical psychologist to ensure that no observer bias was introduced. The results of the six sham studies (table III) were consistent with a random distribution (paired t test).
The results of the third part of the study were as follows (table IV) . In the first 15-minute period (non-activated ultrasonic head with air cell) the mean number of fetal movements was 4-6 i 1-35; in the second period (activated ultrasonic head with air cell) 4-5 ± 0-87; and in the third period (activated ultrasonic head without air cell) 101 1-69. Statistically there was no difference in fetal activity between the first and second periods. The increases in fetal activity between periods 1 and 3 and periods 2 and 3 were significant (P <0 001 and P <0.01 respectively, paired t test).
Discussion
Our results show that Doppler ultrasound as used in obstetrics increases fetal activity. So far as we are aware this has not been reported previously.
The fetal excitatory response to exogenous stimuli such as sound and vibration has been known for over 40 years. ' The fetal response in terms of movement and alterations in heart rate pattern is depressed by narcotics administered to the mother.' A brisk increase of fetal heart rate in response to sound was thought to reflect good fetal condition, but a non-reactive fetus might be asphyxiated, asleep, or under the influence of narcotics.4 Thus, though fetal arousal (when brisk) may predict good fetal outcome, the reverse is not necessarily true. During the past 12 months in our unit four infants have died antenatally. Each mother had reported absent fetal movements for at least 12 hours before the fetal heart became inaudible. During this time each patient underwent external cardiotocography using Doppler ultrasound without fetal response. Other patients who recorded low daily fetal movement counts (below 11/24 h) and in whom the fetal outcome was satisfactory showed an increase in fetal activity during the 24 hours after a one-hour exposure to Doppler ultrasound; however, the reverse was not always true. Though we do not know why the fetus responds to Doppler ultrasound, it is a procedure without known risk,' and we think that with further development the study of this response might provide further information about the fetus.
Introduction
In the management of patients with iron-deficiency anaemia it is generally recommended that oral treatment should be continued for several weeks after the peripheral blood has returned to normal so that iron stores are adequately replenished." 2 The validity of this concept remains unproved as the repeated measurement of body iron stores during treatment has not previously been feasible. Measurement of the serum ferritin concentration, however, provides a simple and accurate means for assessing iron stores,3 and we have used this in patients being treated for simple iron-deficiency anaemia as a guide to the rate at which storage iron accumulates.
Patients and Methods
All the patients studied had iron-deficiency anaemia with a haemoglobin concentration of less than 10 g/dl, a mean corpuscualr volume (M.C.V.) of less than 75 fl, and a mean corpuscular haemoglobin concentration of less than 25 pg. The peripheral blood films all showed hypochromic, microcytic red cells. In all cases the serum iron concentration was less than 7 ,umol/l (39 tg/100 ml), the total iron binding capacity greater than 70 ,umol/l (390 [tg100 ml), and the transferrin saturation less than 10%. The patients were allocated at random to four treatment groups. Group 1 received a total-dose infusion of iron dextran (Imferon) according to the manufacturer's instructions; group 2 ferrous sulphate tablets (200 mg three times daily); group 3 Ferro-Gradumet one tablet daily; and group 4 Ferrograd C one tablet daily. Ferro-Gradumet is a controlled-release preparation containing 525 mg ferrous sulphate in each tablet, while Ferrograd C also contains 500 mg ascorbic acid in each tablet. All patients except those in group 1 were treated until two months after
